Menu ×

HEALTHCARE & PHARMACEUTICAL

Gaucher Disease Market Segmentation By Product Type (Enzyme Replacement Therapy or ERT and Substrate Replacement Therapy or SRT); By Infusion Mode (Intravenous and Oral); By Clinical Type (Type I, Type II and Type III) and By End User (Hospitals, Domestic and Others) - Global Industry Demand Analysis and Opportunity Assessment 2018-2026

  • Text Size:

Inflation And Looming Recession to Haunt Businesses:

In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.

Request Insights

Purchasing power in the couPurchasing power in the country is expected to fell nearly by 2.5%. On the other hand, European countries to see the worst coming in the form of energy crisis especially in upcoming winters!! Right after COVID-19, inflation has started gripping the economies across the globe. Higher than anticipated inflation, especially in western world had raised concerns for national banks and financial institutions to control the economic loss and safeguard the interest of the businesses. Increased interest rates, strong USD inflated oil prices, looming prices for gas and energy resources due to Ukraine-Russia conflict, China economic slowdown (~4% in 2022) disrupting the production and global supply chain and other factors would impact each industry negatively.                                                         Request Insights

Read More

Market Overview

The growth of the global Gaucher disease market is thriving on the back of increasing incidences of Gaucher’s disease as well as the increasing focus of the pharmaceutical companies on introducing new products that cater to the treatment of Gaucher disease. Gaucher disease causes massive clinical heterogeneity with symptoms of painless splenomegaly, anemia or thrombocytopenia, bone pain, chronic fatigue and pathologic fractures and also contributes to easy incidence of bruising and bleeding through the nose. Initially, Gaucher disease was treated in patients by the use of recombinant enzyme imiglucerase which was effective in retrograding the visceral and hematologic symptoms of the disease. With advancements in research and development, the scope for medicine with enhanced treating capabilities is growing significantly. Such factors are considered to promote significantly towards the growth of the global Gaucher disease market.

The global Gaucher disease market reached a value of around USD 1600 million in the year 2018 and is expected to garner a value of around USD 2000 million by the end of 2026 by registering a CAGR of around 3% across the globe over the forecast period 2019-2026. Further, the worldwide market of Gaucher disease is anticipated to achieve a Y-o-Y growth rate of around 3% in the year 2026 as compared to the previous year.

Growth Highlights based on Region during 2018-2026

The global Gaucher disease market is segmented by regions into |North America, Latin America, Europe, Asia Pacific and Middle East and Africa. Among these regions, the market of Asia Pacific Gaucher disease is driven primarily by nations such as China, India and Japan, where China held the dominant market share of around 41% in the year 2018. Presence of the world’s largest population in the nation, which also raises the possibility of being infected by the Gaucher’s disease and the raising concern amongst the population to get vaccinated from such disease are some of the factors that predicts a significant growth of Gaucher disease market in upcoming years. Additionally, Asia Pacific is expected to expand by observing a growth rate of around 1.30x during the assessment period, which in turn is estimated to have a positive effect on the demand for global Gaucher disease treatment in the long run.

Further, U.S. and Canada are the prominent countries that are driving the growth of the North America Gaucher disease market. Increasing expenditure of the government on healthcare sector signifies the growth of the North America Gaucher disease market. CLICK TO DOWNLOAD SAMPLE REPORT

Asia-Pacific-Gaucher-Disease-Market

The study further incorporates Y-O-Y Growth, demand & supply and forecast future opportunity in North America (United States, Canada), Latin America (Brazil, Mexico, Argentina, Rest of LATAM), Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX [Belgium, Netherlands, Luxembourg], NORDIC [Norway, Denmark, Sweden, Finland], Poland, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).

Market Segmentation Synopsis

By Clinical Type

The global Gaucher disease market has been segmented on the basis of clinical type into type I, type II and type III. The type I segment with around 80% share in the year 2018, occupies the largest market of Gaucher disease across the globe. Additionally, the type I segment is anticipated to cross a value of around USD 1500 million by the end of 2026 and is anticipated to flourish at a CAGR of around 3% over the forecast period. Further, the type III segment is estimated to grow with the highest CAGR of around 4% over the forecast period.

Global-Gaucher-Disease-Market

Market Drivers and Challenges

Growth Indicators

There is an increasing concern for the rising incidences of Gaucher disease amongst people around the globe as the risk of developing the disease increases with consanguinity in the family. According to the statistics by the National Organization for Rare Disorders (NORD), around 6000 individuals have Gaucher disease in the United States alone. Although the disease is one of the most common genetic disorder amongst the Ashkenazic Jewish population, which forms about 75% of the world’s total Jewish population, yet the chances of gene mutation or transfer of disease to other individuals often raises the concern to treat these rare diseases in an important manner. Additionally, rising per capita expenditure on healthcare by several nations around the globe along with growing support and funding of the government of nations are some of the factors anticipated to drive the growth of the global Gaucher disease market.

Barriers

The high cost associated with the treatment of the disease and stringent norms of the government of several nations for the use of drugs and treatments of the disease are some of the factors anticipated to impact negatively towards the growth of the global Gaucher disease market.

Competitive Landscape

Some of the affluent industry leaders in the global Gaucher disease market are Protalix Inc., Pfizer Inc., Actelion Pharmaceuticals Ltd., Sanofi and Takeda Pharmaceutical Company Limited.

FREQUENTLY ASKED QUESTIONS

Global Gaucher Disease Market

1. INTRODUCTION

1.1. MARKET DEFINITION

1.2. PURPOSE OF THE REPORT

1.3. CURRENCY

1.4. LIMITATIONS

1.5. STAKEHOLDERS

2. RESEARCH METHODOLOGY

2.1. RESEARCH SCOPE

2.2. MARKET SEGMENTATION

2.3. RESEARCH APPROACH

2.3.1 TOP-DOWN APPROACH

2.3.2 BOTTOM-UP APPROACH

2.4. PRIMARY RESEARCH

2.5. SECONDARY RESEARCH

2.6. ASSUMPTIONS

3. GLOBAL GAUCHER DISEASE MARKET – EXECUTIVE SUMMARY

3.1. SUMMARY

4. GLOBAL GAUCHER DISEASE MARKET OVERVIEW

4.1. MARKET DYNAMICS

4.1.1 DRIVING FORCES

4.1.1.1 Growing incidence of Gaucher disease

4.1.1.2 Increasing governmental support and growing demand for enzyme

replacement therapy for the treatment of rare diseases

4.1.2 RESTRAINING FACTOR

4.1.2.1 High cost of product and therapies

4.1.3 OPPORTUNITY MATRIX

4.1.3.1 Expansion of product portfolio especially in towards Pharmaceutical Products

5. INDUSTRY INSIGHTS

5.1. PORTER'S FIVE FORCES ANALYSIS

5.1.1 BARGAINING POWER OF SUPPLIER

5.1.2 BARGAINING POWER OF BUYER

5.1.3 THREAT OF SUBSTITUTE

5.1.4 THREAT OF NEW ENTRANT

5.1.5 DEGREE OF COMPETITION

5.2. VALUE CHAIN ANALYSIS

6. GLOBAL GAUCHER DISEASE MARKET, BY PRODUCT

6.1. OVERVIEW

7. GLOBAL GAUCHER DISEASE MARKET, BY INFUSION MODES

7.1. OVERVIEW

8. GLOBAL GAUCHER DISEASE MARKET, BY DISTRIBUTION CHANNEL

8.1. OVERVIEW

9. GLOBAL GAUCHER DISEASE MARKET, BY CLINICAL TYPE

9.1. OVERVIEW

10. NORTH AMERICA GAUCHER DISEASE MARKET

10.1. OVERVIEW

10.1.1.1 North America Market Analysis, By Product Type

10.1.1.2 North America Market Analysis, By Intake Mode

10.1.1.3 North America Market Analysis, By Clinical Types

10.1.1.4 North America Market Analysis, By End-Users

10.2. U.S.

10.2.1.1 U.S. Market Analysis, By Product Type

10.2.1.2 U.S. Market Analysis, By Intake Mode

10.2.1.3 U.S. Market Analysis, By Clinical Types

10.2.1.4 U.S. Market Analysis, By End-Users

10.3. CANADA

10.3.1.1 Canada Market Analysis, By Product Type

10.3.1.2 Canada Market Analysis, By Intake Mode

10.3.1.3 Canada Market Analysis, By Clinical Types

10.3.1.4 Canada Market Analysis, By End-Users

11. LATIN AMERICA GAUCHER DISEASE MARKET

11.1. OVERVIEW

11.1.1.1 Latin America Market Analysis, By Product Type

11.1.1.2 Latin America Market Analysis, By Intake Mode

11.1.1.3 Latin America Market Analysis, By Clinical Types

11.1.1.4 Latin America Market Analysis, By End-Users

11.2. BRAZIL

11.2.1.1 Brazil Market Analysis, By Product Type

11.2.1.2 Brazil Market Analysis, By Intake Mode

11.2.1.3 Brazil Market Analysis, By Clinical Types

11.2.1.4 Brazil Market Analysis, By End-Users

11.3. MEXICO

11.3.1.1 Mexico Market Analysis, By Product Type

11.3.1.2 Mexico Market Analysis, By Intake Mode

11.3.1.3 Mexico Market Analysis, By Clinical Types

11.3.1.4 Mexico Market Analysis, By End-Users

11.4. ARGENTINA

11.4.1.1 Argentina Market Analysis, By Product Type

11.4.1.2 Argentina Market Analysis, By Intake Mode

11.4.1.3 Argentina Market Analysis, By Clinical Types

11.4.1.4 Argentina Market Analysis, By End-Users

12. EUROPE GAUCHER DISEASE MARKET

12.1. OVERVIEW

12.1.1.1 Europe Market Analysis, By Product Type

12.1.1.2 Europe Market Analysis, By Intake Mode

12.1.1.3 Europe Market Analysis, By Clinical Types

12.1.1.4 Europe Market Analysis, By End-Users

12.2. GERMANY

12.2.1.1 Germany Market Analysis, By Product Type

12.2.1.2 Germany Market Analysis, By Intake Mode

12.2.1.3 Germany Market Analysis, By Clinical Types

12.2.1.4 Germany Market Analysis, By End-Users 77

12.3. UNITED KINGDOM

12.3.1.1 United Kingdom Market Analysis, By Product Type

12.3.1.2 United Kingdom Market Analysis, By Intake Mode

12.3.1.3 United Kingdom Market Analysis, By Clinical Types

12.3.1.4 United Kingdom Market Analysis, By End-Users

12.4. FRANCE

12.4.1.1 France Market Analysis, By Product Type

12.4.1.2 France Market Analysis, By Intake Mode

12.4.1.3 France Market Analysis, By Clinical Types

12.4.1.4 France Market Analysis, By End-Users

12.5. ITALY

12.5.1.1 Italy Market Analysis, By Product Type

12.5.1.2 Italy Market Analysis, By Intake Mode

12.5.1.3 Italy Market Analysis, By Clinical Types

12.5.1.4 Italy Market Analysis, By End-Users

12.6. SPAIN

12.6.1.1 Spain Market Analysis, By Product Type

12.6.1.2 Spain Market Analysis, By Intake Mode

12.6.1.3 Spain Market Analysis, By Clinical Types

12.6.1.4 Spain Market Analysis, By End-Users

12.7. TURKEY

12.7.1.1 Turkey Market Analysis, By Product Type

12.7.1.2 Turkey Market Analysis, By Intake Mode

12.7.1.3 Turkey Market Analysis, By Clinical Types

12.7.1.4 Turkey Market Analysis, By End-Users

12.8. RUSSIA

12.8.1.1 Russia Market Analysis, By Product Type

12.8.1.2 Russia Market Analysis, By Intake Mode

12.8.1.3 Russia Market Analysis, By Clinical Types

12.8.1.4 Russia Market Analysis, By End-Users

13. ASIA PACIFIC GAUCHER DISEASE MARKET

13.1. OVERVIEW

13.1.1.1 Asia Pacific Market Analysis, By Product Type

13.1.1.2 Asia Pacific Market Analysis, By Intake Mode

13.1.1.3 Asia Pacific Market Analysis, By Clinical Types

13.1.1.4 Asia Pacific Market Analysis, By End-Users

13.2. CHINA

13.2.1.1 China Market Analysis, By Product Type

13.2.1.2 China Market Analysis, By Intake Mode

13.2.1.3 China Market Analysis, By Clinical Types

13.2.1.4 China Market Analysis, By End-Users

13.3. INDIA

13.3.1.1 India Market Analysis, By Product Type

13.3.1.2 India Market Analysis, By Intake Mode

13.3.1.3 India Market Analysis, By Clinical Types

13.3.1.4 India Market Analysis, By End-Users

13.4. JAPAN

13.4.1.1 Japan Market Analysis, By Product Type

13.4.1.2 Japan Market Analysis, By Intake Mode

13.4.1.3 Japan Market Analysis, By Clinical Types

13.4.1.4 Japan Market Analysis, By End-Users

13.5. SOUTH KOREA

13.5.1.1 South Korea Market Analysis, By Product Type

13.5.1.2 South Korea Market Analysis, By Intake Mode

13.5.1.3 South Korea Market Analysis, ByClinical Types

13.5.1.4 South Korea Market Analysis, By End-Users

13.6. AUSTRALIA

13.6.1.1 Australia Market Analysis, By Product Type

13.6.1.2 Australia Market Analysis, By Intake Mode

13.6.1.3 Australia Market Analysis, By Clinical Types

13.6.1.4 Australia Market Analysis, By End-Users

14. MIDDLE EAST AND AFRICA (MEA) GAUCHER DISEASE MARKET

14.1. OVERVIEW

14.1.1.1 MEA Market Analysis, By Product Type

14.1.1.2 MEA Market Analysis, By Intake Mode

14.1.1.3 MEA Market Analysis, By Clinical Types

14.1.1.4 MEA Market Analysis, By End-Users

14.2. SOUTH AFRICA

14.2.1.1 South Africa Market Analysis, By Product Type

14.2.1.2 South Africa Market Analysis, By Intake Mode

14.2.1.3 South Africa Market Analysis, By Clinical Types

14.2.1.4 South Africa Market Analysis, By End-Users

14.3. SAUDI ARABIA

14.3.1.1 Saudi Arabia Market Analysis, By Product Type

14.3.1.2 Saudi Arabia Market Analysis, By Intake Mode

14.3.1.3 Saudi Arabia Market Analysis, By Clinical Types

14.3.1.4 Saudi Arabia Market Analysis, By End-Users

14.4. ISRAEL

14.4.1.1 Israel Market Analysis, By Product Type

14.4.1.2 Israel Market Analysis, By Intake Mode

14.4.1.3 Israel Market Analysis, By Clinical Types

14.4.1.4 Israel Market Analysis, By End-Users

14.5. UAE

14.5.1.1 UAE Market Analysis, By Product Type

14.5.1.2 UAE Market Analysis, By Intake Mode

14.5.1.3 UAE Market Analysis, By Clinical Types

14.5.1.4 UAE Market Analysis, By End-Users

15. COMPANY PROFILES

15.1. PROTALIX BIOTHERAPEUTICS INC

15.1.1 COMPANY OVERVIEW

15.1.2 FINANCIAL PERFORMANCE

15.1.3 PRODUCT PORTFOLIO

15.2. PFIZER INC

15.2.1 COMPANY OVERVIEW

15.2.2 FINANCIAL PERFORMANCE

15.2.3 PRODUCT PORTFOLIO

15.3. ACTELION PHARMACEUTICALS LTD

15.3.1 COMPANY OVERVIEW

15.3.2 PRODUCT PORTFOLIO

15.3.3 RECENT DEVELOPMENT

15.4. SANOFI SA

15.4.1 COMPANY OVERVIEW

15.4.2 FINANCIAL PERFORMANCE

15.4.3 PRODUCT PORTFOLIO

15.5. TAKEDA PHARMACEUTICAL CO LTD

15.5.1 COMPANY OVERVIEW

15.5.2 FINANCIAL PERFORMANCE

15.5.3 PRODUCT PORTFOLIO

15.5.4 RECENT DEVELOPMENT


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions | LOB

Copyright © 2022 Research Nester. All Rights Reserved